United States: Two Favorable Tysabri Rulings Add Clarity To "Clear Evidence" Preemption Standard – And More

Last Updated: August 15 2016
Article by James Beck

Anyone who has checked our post-Levine innovator drug & vaccine cheat sheet lately has no doubt noticed our two most recent entries, Gentile v. Biogen Idec, Inc., 2016 WL 4128159 (Mass. Super. July 25, 2016), and Christison v. Biogen Idec Inc., No. 2:11-CV-01140-DN-DBP, slip op. (D. Utah Aug. 5, 2016). With respect to preemption and innovator drug warnings, these cases provide further support to an emerging, common-sense bright line in the otherwise all-too-murky world of "clear evidence" – that a warning change rejected by the FDA for lack of scientific evidence must be "clear evidence" that this change would have also been rejected at any earlier date. The logic is inescapable that, if there was insufficient scientific evidence at moment X, there is no more, and usually less, evidence on the same issue at any time before X.

Looking at our cheat sheet, the first case to so hold appears to be In re Fosamax (Alendronate Sodium) Products Liability Litigation, 951 F. Supp.2d 695 (D.N.J. 2013). Fosamax involved the FDA's partial rejection of a prior approval supplement after the date of the plaintiff's injury. Id. at 703 (FDA rejection occurred "approximately one month after" plaintiff's injury). The label change failed because "the data that FDA has reviewed have not shown a clear connection" between the drug and the risk at issue. Id. at 699.

[C]lear evidence exists that the FDA would not have approved a label change to the Precautions section of the [drug] label prior to [plaintiff's] fracture because Defendant submitted a label change and the FDA rejected it, and the FDA never required Defendant to submit new language or change the label, which demonstrates that the FDA did not think that the label should have been changed at that time.

Id. at 703-04. See In re Fosamax Alendronate Sodium Products Liability Litigation, 2014 WL 1266994, at *11 (D.N.J. March 26, 2014) (applying this ruling "to those Plaintiffs' whose injuries occurred prior to [the FDA rejection date], without allowing additional discovery").

Similar decisions – based on FDA insufficient-evidence rejections of label changes that occurred after the plaintiff's prescription/treatment/injury – have also occurred in two Depakote cases: In re Depakote, 87 F. Supp.3d 916 (S.D. Ill. 2015), and Rheinfrank v. Abbott Laboratories, Inc., 119 F. Supp.3d 749 (S.D. Ohio), reconsideration denied, 137 F. Supp.3d 1035 (S.D. Ohio 2015).

In light of the fact that the FDA rejected the [particular risk] warning in 2006 because it did not find that the available scientific evidence at that time supported the addition of such a warning, it is highly unlikely that the available scientific evidence, seven years prior to that date in 1999, would have supported the addition of such a warning.

Depakote, 87 F. Supp.3d at 922 (emphasis original).

Preemption is warranted because there is clear evidence the FDA would not have approved a change to the [drug] label adding a [particular risk] warning prior to [plaintiff's] injury. The Court finds the FDA's February 2006 decision that [these] warnings "should not be incorporated into [the drug's] labeling" and the FDA's 2008 belief that "the data do not provide sufficient evidence to support [] labeling changes at this time" constitute "clear evidence" that when confronted by the issue in 2003, the FDA would have rejected an attempt to add a [the same risk] warning.

Rheinfrank, 119 F. Supp.3d at 766. Cf. In re Incretin-Based Therapies Products Liability Litigation, 142 F. Supp. 3d 1108, 1124-27 (S.D. Cal. 2015) (multiple, recent FDA insufficient evidence conclusions supported "clear evidence" preemption regardless of individual plaintiff prescription or injury dates); In re Byetta Cases, 2015 WL 7184655, at *13-14 (Cal. Super. Nov. 13, 2015) (same).

Several months ago, we discussed another case drawing the same line, Cerveny v. Aventis, Inc., ___ F. Supp.3d ___, 2016 WL 1065826 (D. Utah March 16, 2016). In Cerveny, two FDA citizen's petition denials for "fail[ure] to provide reasonable evidence to demonstrate" a causal connection to the alleged risk doomed product liability claims based on a prescription that was made prior to those denials:

[W]here a citizen petition post-dates the alleged injury and addresses the failure-to-warn claim proffered by a plaintiff, a citizen petition denial can be evidence to support a manufacturer's preemption defense. . . . In this case, the FDA heard and rejected the Plaintiffs' theory embodied in [the] citizen petitions, which post-dates [plaintiff's drug] use. . . . If the FDA concluded in 2009 and 2012 that [the drug] . . . does not pose a risk of [what plaintiff suffered], the Court cannot say the FDA would have approved a contrary warning prior to 1992. . . . The FDA's denial of the Plaintiffs' theories embodied in [the] citizen petitions is clear evidence that the FDA would not have permitted [defendant] to strengthen [the drug's] label prior to 1992.

Id. at *9-11 (numerous citations omitted)

The Gentile and Christison Tysabri cases follow this line of precedent – and more. In these cases, the link between the drug in question and the rare, fatal condition that the plaintiffs alleged was undisputed – and quite graphically warned about (more on that after we finish with preemption). However, the drug was very useful against other, more common, and likewise potentially fatal conditions, and at the time(s) in question, there was essentially nothing predictive of who would suffer the rare risk. Gentile, 2016 WL 4128159, at *1-3; Christison, slip op. at 6, 9-15. In both cases, the plaintiffs focused on the potential value of certain antibody tests, but both of them used the drug prior to FDA approval of those tests. In 2006 FDA determined that "no consensus" existed on whether those tests were "clinically relevant." Gentile, 2016 WL 4128159, at *2-3; Christison, slip op. at 15. In 2010, the FDA reached the same conclusion – "that there is currently sufficient information to support the clinical utility of the . . . antibody assay in determining the risk." Gentile, 2016 WL 4128159, at *3; Christison, slip op. at 47. Ultimately, after additional study and submissions, the FDA approved an antibody-based test for risk susceptibility in 2012. Gentile, 2016 WL 4128159, at *3; Christison, slip op. at 15-16.

In both Gentile and Christison, the relevant use of the drug occurred prior to one or both of the FDA's 2006 and 2010 insufficient evidence-based refusals to approve the antibody tests. Gentile, 2016 WL 4128159, at *2-3 (used drug between January, 2007 and September, 2009); Christison, slip op. at 18-20 (used drug between February, 2007 and June, 2009). Given that, even after the last prescriptions, the FDA had considered and refused to approve the tests at issue due to insufficient scientific support, both cases concluded that "clear evidence" existed to support preemption of warning claims asserting that the tests should have been recommended in the drug's labeling.

In the present case, the FDA's decision to reject the proposed modifications regarding risks associated with providing [the drug] to patients with the [] antibody demonstrates that prior to [plaintiff's decedent's] diagnosis, defendants could not have strengthened their warnings to comply with state law without violating the FDA's decision. . . . Here, FDA rejected defendants' proposed change in the warning not because of the language used, but because the supporting data was not yet sufficiently persuasive. For this reason, summary judgment is further appropriate, at least in part, because plaintiff's claims, insofar as they are based on defendants' allegedly inadequate warnings about the risks of administering [the drug] to patients who are found to have [the] antibodies, are preempted by federal law.

Gentile, 2016 WL 4128159, at *8-9 (citation omitted).

The Companies are correct that if [the data] were insufficient to persuade FDA in 2010 of the predictive value of antibody testing . . ., there clearly would not have been sufficient data more than two years earlier. Accordingly, there is "clear evidence" that the FDA would not have approved a change to the [drug] label prior to [plaintiff's decedent's] death, and the causes of action that [plaintiff] raises in this matter − negligence; negligent failure to warn; and negligent misrepresentation − which are based in state law, are preempted by federal requirements mandating FDA approval of changes to a drug's warning label.

Christison, slip op. at 48 (citations, quotation marks, and footnote omitted).

One of the biggest problems with the Levine "clear evidence" test is that it is so bound up in the facts of any individual case that precedent has been of limited value, and courts have reached inconsistent results on the same facts. Gentile and Christison demonstrate that, at least on one front, it is now possible to draw a bright line in post-Levine "clear evidence" preemption cases – If the FDA finds insufficient evidence to support a label change on a given date, then logically any warning claim based on prescriptions that occurred before that FDA action will be preempted, because even less scientific evidence than what the FDA found wanting will necessarily exist during an earlier time period. As we've just discussed, this principle can be applied to a variety of branded (and, indeed, OTC) drugs.

But there's more – considerably more. The warnings and special prescription protocol that surround the use of Tysabri are detailed and extensive (far longer than we would quote here), as befits the magnitude of the risk (an almost always fatal condition) involved. They are as impressive as the warnings and related special precautions that attend use of Accutane. Accutane cases have produced quite a few favorable decisions concerning the adequacy of challenged warnings. See, e.g., Felix v. Hoffmann-LaRoche, Inc., 540 So.2d 102, 105 (Fla. 1989); Banner v. Hoffmann-La Roche Inc., 891 A.2d 1229, 1239 (N.J. Super. App. Div. 2006); In re Accutane Products Liability Litigation, 2012 WL 3194954, at *5 (M.D. Fla. July 24, 2012); Gerber v. Hoffmann-La Roche Inc., 392 F. Supp.2d 907, 915-18 (S.D. Tex. 2005). The same thing occurred here. The courts in both Gentile and Christison held that the warnings at issue were adequate as a matter of law:

Because [the condition] may lead to death or severe disability, the warnings should have been commensurate with a high level of risk. The black box warning in effect when [the prescriber] first prescribed [the drug] to [the decedent] explicitly warned against the precise risk . . . that [the decedent] ultimately suffered, and fully disclosed the serious consequences of that disease. . . . [W]hen read as a whole, the warnings unmistakably conveyed the seriousness of [the risk] and its association with [the drug's] treatment.

Gentile, 2016 WL 4128159, at *6 (applying New York law) 2016 WL 4128159 (citations omitted).

The Companies are correct that the labeling is adequate as a matter of law. . . . the Companies provided an adequate warning because the [the drug's] warning (1) was designed so it could reasonably be expected to catch the attention of the consumer; (2) was comprehensible and gave a fair indication of the specific risks involved with [the drug]; and (3) was of an intensity justified by the magnitude of the risk.

Christison, slip op. at 40-41.

And more: The plaintiff's expert testimony was deficient with respect to the adequacy of the warnings. In Gentile, because the learned intermediary rule applied, the plaintiff needed a physician to testify to the inadequacy of warnings to the medical profession. 2016 WL 4128159, at *7 (plaintiff's expert "is not a medical doctor, does not have the qualifications necessary to opine on matters of treating patients, and does not assert that he has the experience necessary to interpret warnings from the perspective of a prescribing physician"). In Christison, the plaintiff failed to offer any warning expert at all.

[Plaintiff] is incorrect. A lay jury is not able to call on "their own life experiences" to determine the adequacy of a drug label. Where the injury involves obscure medical factors which are beyond an ordinary lay person's knowledge, necessitating speculation in making a finding, there must be expert testimony that the defendant's conduct probably caused the injury. . . . A lay jury would not be able to determine by calling upon "their own life experiences" and would be speculating in making findings about the adequacy of the [drug's] warning label, which warned extensively about [the risk].

Slip op. at 36-37 (footnote omitted). See Id. at 37 (plaintiff must have expert testimony "on what 'a more adequate label' would contain") (footnote omitted).

And in Gentile still more – enough that, in our opinion, Gentile is the best trial court opinion ever to emerge from a Massachusetts trial court in a drug or medical device case. Specifically:

  • Warning causation: The plaintiff's attempted nit-picking of the warnings in Gentile also failed because the prescribing surgeon's decision "would not have changed" with the additional information. 2016 WL 4128159, at *7.
  • Good Samaritan liability: "[P]laintiff cannot prove defendants voluntarily assumed a duty to warn [the decedent] by providing her with information directly, and not through her doctor." Id. at *8.
  • Design defect/comment k: "New York does not recognize a design defect theory of liability for prescription medicines" because a drug with adequate warnings is "not defective." Id.
  • Mensing-style preemption for innovator drugs: All warning claims against the distributor defendant were preempted because it was impossible for the distributor to alter drug warnings because it was not the holder of the FDA new drug application. Id. at *9 (another company "is the holder of the original, approved application for [the drug]. Consequently, [the distributor] could not have sought modifications of the label").

Innovator drug preemption (2 kinds), warning adequacy as a matter of law, learned intermediary rule-based expert requirements, warning causation, design defect, and assumed duty – that's a bunch of significant rulings. We'll certainly be watching out for similar cases coming down the pike in the future, but given the thankfully rare nature of the risk involved, there probably won't be that many.

This article is presented for informational purposes only and is not intended to constitute legal advice.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

Authors
James Beck
 
In association with
Related Video
Up-coming Events Search
Tools
Print
Font Size:
Translation
Channels
Mondaq on Twitter
 
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
 
Email Address
Company Name
Password
Confirm Password
Position
Mondaq Topics -- Select your Interests
 Accounting
 Anti-trust
 Commercial
 Compliance
 Consumer
 Criminal
 Employment
 Energy
 Environment
 Family
 Finance
 Government
 Healthcare
 Immigration
 Insolvency
 Insurance
 International
 IP
 Law Performance
 Law Practice
 Litigation
 Media & IT
 Privacy
 Real Estate
 Strategy
 Tax
 Technology
 Transport
 Wealth Mgt
Regions
Africa
Asia
Asia Pacific
Australasia
Canada
Caribbean
Europe
European Union
Latin America
Middle East
U.K.
United States
Worldwide Updates
Check to state you have read and
agree to our Terms and Conditions

Terms & Conditions and Privacy Statement

Mondaq.com (the Website) is owned and managed by Mondaq Ltd and as a user you are granted a non-exclusive, revocable license to access the Website under its terms and conditions of use. Your use of the Website constitutes your agreement to the following terms and conditions of use. Mondaq Ltd may terminate your use of the Website if you are in breach of these terms and conditions or if Mondaq Ltd decides to terminate your license of use for whatever reason.

Use of www.mondaq.com

You may use the Website but are required to register as a user if you wish to read the full text of the content and articles available (the Content). You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these terms & conditions or with the prior written consent of Mondaq Ltd. You may not use electronic or other means to extract details or information about Mondaq.com’s content, users or contributors in order to offer them any services or products which compete directly or indirectly with Mondaq Ltd’s services and products.

Disclaimer

Mondaq Ltd and/or its respective suppliers make no representations about the suitability of the information contained in the documents and related graphics published on this server for any purpose. All such documents and related graphics are provided "as is" without warranty of any kind. Mondaq Ltd and/or its respective suppliers hereby disclaim all warranties and conditions with regard to this information, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. In no event shall Mondaq Ltd and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use or performance of information available from this server.

The documents and related graphics published on this server could include technical inaccuracies or typographical errors. Changes are periodically added to the information herein. Mondaq Ltd and/or its respective suppliers may make improvements and/or changes in the product(s) and/or the program(s) described herein at any time.

Registration

Mondaq Ltd requires you to register and provide information that personally identifies you, including what sort of information you are interested in, for three primary purposes:

  • To allow you to personalize the Mondaq websites you are visiting.
  • To enable features such as password reminder, newsletter alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our information providers who provide information free for your use.

Mondaq (and its affiliate sites) do not sell or provide your details to third parties other than information providers. The reason we provide our information providers with this information is so that they can measure the response their articles are receiving and provide you with information about their products and services.

If you do not want us to provide your name and email address you may opt out by clicking here .

If you do not wish to receive any future announcements of products and services offered by Mondaq by clicking here .

Information Collection and Use

We require site users to register with Mondaq (and its affiliate sites) to view the free information on the site. We also collect information from our users at several different points on the websites: this is so that we can customise the sites according to individual usage, provide 'session-aware' functionality, and ensure that content is acquired and developed appropriately. This gives us an overall picture of our user profiles, which in turn shows to our Editorial Contributors the type of person they are reaching by posting articles on Mondaq (and its affiliate sites) – meaning more free content for registered users.

We are only able to provide the material on the Mondaq (and its affiliate sites) site free to site visitors because we can pass on information about the pages that users are viewing and the personal information users provide to us (e.g. email addresses) to reputable contributing firms such as law firms who author those pages. We do not sell or rent information to anyone else other than the authors of those pages, who may change from time to time. Should you wish us not to disclose your details to any of these parties, please tick the box above or tick the box marked "Opt out of Registration Information Disclosure" on the Your Profile page. We and our author organisations may only contact you via email or other means if you allow us to do so. Users can opt out of contact when they register on the site, or send an email to unsubscribe@mondaq.com with “no disclosure” in the subject heading

Mondaq News Alerts

In order to receive Mondaq News Alerts, users have to complete a separate registration form. This is a personalised service where users choose regions and topics of interest and we send it only to those users who have requested it. Users can stop receiving these Alerts by going to the Mondaq News Alerts page and deselecting all interest areas. In the same way users can amend their personal preferences to add or remove subject areas.

Cookies

A cookie is a small text file written to a user’s hard drive that contains an identifying user number. The cookies do not contain any personal information about users. We use the cookie so users do not have to log in every time they use the service and the cookie will automatically expire if you do not visit the Mondaq website (or its affiliate sites) for 12 months. We also use the cookie to personalise a user's experience of the site (for example to show information specific to a user's region). As the Mondaq sites are fully personalised and cookies are essential to its core technology the site will function unpredictably with browsers that do not support cookies - or where cookies are disabled (in these circumstances we advise you to attempt to locate the information you require elsewhere on the web). However if you are concerned about the presence of a Mondaq cookie on your machine you can also choose to expire the cookie immediately (remove it) by selecting the 'Log Off' menu option as the last thing you do when you use the site.

Some of our business partners may use cookies on our site (for example, advertisers). However, we have no access to or control over these cookies and we are not aware of any at present that do so.

Log Files

We use IP addresses to analyse trends, administer the site, track movement, and gather broad demographic information for aggregate use. IP addresses are not linked to personally identifiable information.

Links

This web site contains links to other sites. Please be aware that Mondaq (or its affiliate sites) are not responsible for the privacy practices of such other sites. We encourage our users to be aware when they leave our site and to read the privacy statements of these third party sites. This privacy statement applies solely to information collected by this Web site.

Surveys & Contests

From time-to-time our site requests information from users via surveys or contests. Participation in these surveys or contests is completely voluntary and the user therefore has a choice whether or not to disclose any information requested. Information requested may include contact information (such as name and delivery address), and demographic information (such as postcode, age level). Contact information will be used to notify the winners and award prizes. Survey information will be used for purposes of monitoring or improving the functionality of the site.

Mail-A-Friend

If a user elects to use our referral service for informing a friend about our site, we ask them for the friend’s name and email address. Mondaq stores this information and may contact the friend to invite them to register with Mondaq, but they will not be contacted more than once. The friend may contact Mondaq to request the removal of this information from our database.

Security

This website takes every reasonable precaution to protect our users’ information. When users submit sensitive information via the website, your information is protected using firewalls and other security technology. If you have any questions about the security at our website, you can send an email to webmaster@mondaq.com.

Correcting/Updating Personal Information

If a user’s personally identifiable information changes (such as postcode), or if a user no longer desires our service, we will endeavour to provide a way to correct, update or remove that user’s personal data provided to us. This can usually be done at the “Your Profile” page or by sending an email to EditorialAdvisor@mondaq.com.

Notification of Changes

If we decide to change our Terms & Conditions or Privacy Policy, we will post those changes on our site so our users are always aware of what information we collect, how we use it, and under what circumstances, if any, we disclose it. If at any point we decide to use personally identifiable information in a manner different from that stated at the time it was collected, we will notify users by way of an email. Users will have a choice as to whether or not we use their information in this different manner. We will use information in accordance with the privacy policy under which the information was collected.

How to contact Mondaq

You can contact us with comments or queries at enquiries@mondaq.com.

If for some reason you believe Mondaq Ltd. has not adhered to these principles, please notify us by e-mail at problems@mondaq.com and we will use commercially reasonable efforts to determine and correct the problem promptly.